Welcome to our dedicated page for Phathom Pharmaceuticals SEC filings (Ticker: PHAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Phathom is a biopharmaceutical company focused on gastrointestinal (GI) diseases, and its filings offer detailed information on VOQUEZNA (vonoprazan) commercialization, clinical programs, and corporate activity.
Through current reports on Form 8-K, Phathom reports material events such as quarterly and interim financial results, clinical trial milestones, leadership changes, and key scientific publications. For example, the company has used Form 8-K to announce financial results for specific quarters, publication of additional analyses from the Phase 3 pHalcon-NERD-301 trial in Non-Erosive GERD, and initiation of the Phase 2 pHalcon-EoE-201 study in eosinophilic esophagitis.
Filings also document capital markets transactions, including underwritten public offerings of common stock and pre-funded warrants, and provide details on the intended use of proceeds for working capital, commercialization, and research and development expenses. Disclosures about executive appointments and compensation arrangements, such as the appointment of a Chief Financial and Business Officer, are likewise reported in 8-K filings.
On Stock Titan, these SEC documents are complemented by AI-powered summaries that highlight the key points of lengthy filings, helping readers quickly understand topics such as operating performance, clinical trial updates, and corporate governance changes. Users can monitor real-time updates from EDGAR, review quarterly and annual reports when available, and examine current reports for insights into Phathom’s GI-focused business. This page serves as a central resource for investors and researchers who want to analyze PHAT’s official disclosures alongside concise AI-generated explanations.
Phathom Pharmaceuticals reported an insider equity transaction by its President and CEO and director, Steven L. Basta. On 11/28/2025, 90,000 shares of common stock were acquired through the exercise of performance stock units at an exercise price of $0, increasing his directly held common stock to 131,625 shares before tax settlements.
On the same date, 48,375 shares of common stock were surrendered at a price of $15.62 to cover tax withholding obligations, leaving 83,250 common shares held directly after the transactions. The derivative table shows performance share units with 90,000 shares underlying this exercise and 180,000 derivative securities remaining beneficially owned. The filing explains that 360,000 performance stock units were granted on April 3, 2025, with vesting tied to stock price hurdles over four years and continued service.
Phathom Pharmaceuticals (PHAT) insider filing: The company’s Principal Accounting Officer reported a sale of common stock on 11/03/2025. The filing shows 524 shares sold at $13.51 (transaction code S).
The footnote states the shares were sold to satisfy tax withholding obligations upon the settlement of restricted stock units. Following the transaction, beneficial ownership stands at 47,407 shares held directly and 6,945.4 shares held indirectly via a 401(k).
Phathom Pharmaceuticals announced the first patient has been dosed in its Phase 2 pHalcon EoE-201 trial evaluating VOQUEZNA (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis in adults.
The study is a two-part, randomized, double-blind, placebo-controlled trial. Part 1 will enroll 80 adults with endoscopic-confirmed EoE and dysphagia, randomized to VOQUEZNA 20 mg or placebo once daily for 12 weeks. Patients who complete Part 1 may enter a 12-week extension (Part 2), where all participants receive VOQUEZNA 20 mg.
Topline primary and secondary results are anticipated in 2027. The company also noted typical development uncertainties and forward-looking risks related to study conduct, enrollment, outcomes, and future program decisions.
Phathom Pharmaceuticals (PHAT) reported Q3 2025 results with product revenue of $49.5 million, up from $16.4 million a year ago as VOQUEZNA sales expanded. Gross profit reached $43.3 million and operating loss narrowed to $15.3 million. Net loss was $30.0 million, or $0.41 per share, versus $85.6 million, or $1.32 per share, last year.
For the first nine months, product revenue totaled $117.5 million versus $25.6 million in 2024, and net loss improved to $200.1 million from $259.9 million. Cash and cash equivalents were $135.2 million, with stockholders’ deficit at $422.5 million. Long‑term debt, net, was $207.1 million, and the revenue interest financing liability stood at $373.3 million (including $24.3 million current). The company recorded $9.2 million of restructuring charges in May to streamline operations.
Management states it has sufficient working capital for at least the next twelve months. An at‑the‑market program for up to $150 million remains unused. Shares outstanding were 71,138,440 as of October 27, 2025.
Phathom Pharmaceuticals furnished a press release announcing financial results for the quarter ended September 30, 2025. The release was provided as Exhibit 99.1 to an Item 2.02 report.
Under General Instruction B.2, the information in the report, including Exhibit 99.1, is treated as furnished and not filed.
Phathom Pharmaceuticals (PHAT) reported that additional analyses from its pivotal Phase 3 pHalcon-NERD-301 trial of VOQUEZNA (vonoprazan) in Non-Erosive Reflux Disease were published in the American Journal of Gastroenterology. The article, “Vonoprazan Improves Nocturnal Gastroesophageal Reflux Symptoms in Non-Erosive Reflux Disease,” highlights the burden of nighttime GERD symptoms.
In the trial, 772 patients were randomized to VOQUEZNA 10 mg, 20 mg, or placebo for 4 weeks, followed by a 20-week extension with active treatment. Nighttime GERD symptoms affect up to an estimated 80% of patients and are linked to impaired sleep and productivity. The company also included standard forward-looking statement cautions about clinical performance and market acceptance.
Sanjeev Narula, Chief Financial & Business Officer of Phathom Pharmaceuticals, Inc. (PHAT), reported a grant of 144,000 restricted stock units (RSUs) on
Phathom Pharmaceuticals, Inc. (PHAT) reported a Section 16 officer equity award for Chief Financial & Business Officer Sanjeev Narula. On
The award vests 25% on
Initial Form 3 filed for Sanjeev Narula. The filing reports a Date of Event of 10/06/2025 and identifies the reporting person as Sanjeev Narula with an address at 100 Campus Drive, Suite 102, Florham Park, NJ 07932. The form indicates the reporting person is an Officer with the title Chief Financial & Bus. Officer. The report discloses no non-derivative or derivative securities beneficially owned (listed as 0 and no securities are beneficially owned). The signature on the filing is by an attorney-in-fact dated 10/07/2025.
Phathom Pharmaceuticals appointed Sanjeev Narula as its Chief Financial and Business Officer and principal financial officer, effective October 6, 2025, replacing Robert Breedlove in the principal financial officer role while he remains principal accounting officer. Mr. Narula will receive an initial annual base salary of $550,000 and be eligible for an annual target bonus equal to 50% of base salary, with a prorated bonus opportunity for 2025.
His employment agreement provides severance if he is terminated without cause or resigns for good reason, including up to 9 months of base salary, a prorated target bonus, certain unpaid bonuses, company-paid COBRA premiums during the severance period, and partial acceleration of time-based equity awards. If such a termination occurs within the defined change in control period, the severance period increases to 18 months, the cash bonus multiple increases to 1.5x target bonus, and all unvested time-based equity awards vest in full, with performance-based awards governed by their own terms.
On October 6, 2025, Phathom granted Mr. Narula stock options to purchase 200,000 shares of common stock vesting over four years and 144,000 restricted stock units vesting in three annual installments, all under the company’s 2019 Incentive Award Plan and subject to continued employment.
FAQ
What is the current stock price of Phathom Pharmaceuticals (PHAT)?
What is the market cap of Phathom Pharmaceuticals (PHAT)?
